
51 - 200 employees
Founded 2013
🧬 Biotechnology
🏥 Healthcare
💰 $14.4M Funding Round - Cleveland Diagnostics on 2025-10
Biotechnology • Healthcare
Cleveland Diagnostics is a molecular diagnostics company developing blood-based cancer tests using its IsoClear™ platform, which measures structural differences in proteins to determine whether biomarkers originated in cancer cells. Their first commercial test, IsoPSA, aims to improve prostate cancer decision-making by identifying risk of high-grade disease and can reduce unnecessary prostate biopsies; the IsoPSA test is offered as a laboratory-developed test (LDT) performed in CLIA-certified, high-complexity laboratories and has not been FDA-cleared.
📡 We watch Cleveland Diagnostics's careers page
Several times a day
how often we check
1
roles posted in the last 30 days
4
roles closed in the last year
Selected: 🆕 Date Added.
🕒 August 25
Field Applications Specialist implementing Cleveland Diagnostics’ cancer diagnostic tests in customer laboratories. Leading assay validation, training, LIS integration, and ongoing technical support with 80% travel.
🏈 Ohio – Remote
💵 $80k - $100k / year
🔥 Funding within the last year
💰 $14.4M Funding Round - Cleveland Diagnostics on 2025-10
⏰ Full Time
🟡 Mid-level
👻 Ghost score 24%
🕒 July 27
Senior Manager/Associate Director of Market Access & Reimbursement for Cleveland Diagnostics. Responsible for commercial coverage strategy ensuring patient access to diagnostics technologies.
🇺🇸 United States – Remote
💵 $85k - $150k / year
🔥 Funding within the last year
💰 $14.4M Funding Round - Cleveland Diagnostics on 2025-10
⏰ Full Time
🔴 Lead
👔 Director
👻 Ghost score 37%
🕒 July 27
Account Executive responsible for building relationships and achieving sales targets in Urology market. Engaging with key decision makers and utilizing Salesforce to manage prospects.
🇺🇸 United States – Remote
💵 $85k - $95k / year
🔥 Funding within the last year
💰 $14.4M Funding Round - Cleveland Diagnostics on 2025-10
⏰ Full Time
🟢 Junior
🧑💼 Account Executive
👻 Ghost score 37%